Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 6/20 | 0.38 |
| ▸ | FNTB | P49356 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708803 | 0.86 | NOD2 (0.47) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL26930708 | 0.86 | NOD2 (0.47) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL26931200 | 0.84 | FNTA (0.45) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL26930792 | 0.84 | FNTA (0.53) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL26931128 | 0.82 | FNTA (0.54) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL27165736 | 0.82 | FNTA (0.54) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL31338818 | 0.79 | FNTA (0.42) | MAPTFNTAFNTBKDM4ERXFP1 | |
| SCHEMBL30708759 | 0.74 | ALDH1A1 (0.44) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL26931196 | 0.74 | ALDH1A1 (0.44) | MAPTFNTAFNTBKDM4ENOD2 | |
| SCHEMBL24749013 | 0.74 | ALDH1A1 (0.35) | MAPTFNTAFNTBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938120-B1 | Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents | King Faisal University (SA) | 2024-03-26 | — | — | US | claimed |
| US-11845746-B1 | Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents | King Faisal University (SA) | 2023-12-19 | — | — | US | claimed |
| US-11938120-B1 | Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents | King Faisal University (SA) | 2024-03-26 | — | — | US | disclosed |
| US-11845746-B1 | Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents | King Faisal University (SA) | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845746-B1 | Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents | BET1, RABGGTB, EP300 | MAPT 2304/4885FNTA 962/4885FNTB 51/4885 |
| US-11938120-B1 | Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents | BET1, RABGGTB, EP300 | MAPT 2370/4885FNTA 1019/4885FNTB 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.